Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2017; 23(15): 2743-2749
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2743
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2743
Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening
Masau Sekiguchi, Yasuo Kakugawa, Takahisa Matsuda, Cancer Screening Center, National Cancer Center Hospital, Tokyo 104-0045, Japan
Masau Sekiguchi, Yasuo Kakugawa, Yutaka Saito, Takahisa Matsuda, Endoscopy Division, National Cancer Center Hospital, Tokyo 104-0045, Japan
Masau Sekiguchi, Takahisa Matsuda, Division of Screening Technology, Center for Public Health Sciences, National Cancer Center, Tokyo 104-0045, Japan
Takashi Terauchi, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan
Takashi Terauchi, Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 104-0045, Japan
Naoki Shimada, Department of Radiological Technology Radiological Diagnosis, National Cancer Center Hospital, Tokyo 104-0045, Japan
Author contributions: Sekiguchi M designed the study, analyzed and interpreted the data, and drafted the article; Terauchi T, Kakugawa Y, Shimada N, Saito Y, and Matsuda T collected, analyzed and interpreted the data, and contributed to the critical revision of the article for important intellectual content; all authors had final approval of the article.
Supported by (in part) the National Cancer Center Research and Development Fund , No. 27-A-5 .
Institutional review board statement: This study was reviewed and approved by the Ethics Committee for Clinical Research of the National Cancer Center.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None of the authors report a conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Masau Sekiguchi, MD, Cancer Screening Center, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. masekigu@ncc.go.jp
Telephone: +81-3-35422511 Fax: +81-3-35423815
Received: January 6, 2017
Peer-review started: January 9, 2017
First decision: February 9, 2017
Revised: February 23, 2017
Accepted: March 20, 2017
Article in press: March 20, 2017
Published online: April 21, 2017
Processing time: 103 Days and 22.7 Hours
Peer-review started: January 9, 2017
First decision: February 9, 2017
Revised: February 23, 2017
Accepted: March 20, 2017
Article in press: March 20, 2017
Published online: April 21, 2017
Processing time: 103 Days and 22.7 Hours
Core Tip
Core tip: The present study first clarified the performance of 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) for esophageal cancer screening by adopting an appropriate study method. A large number of asymptomatic screened individuals who underwent both FDG-PET and esophagogastroduodenoscopy were included in the study, and the performance of FDG-PET was assessed by comparing the results of FDG-PET and esophagogastroduodenoscopy, considering the latter as the reference. As a result, the low screen sensitivity (3.6%) and positive predictive value (2.0%) of FDG-PET for esophageal cancer were clearly shown. Based on the results, FDG-PET is considered to be difficult to use as a screening modality for esophageal cancer.